Concepedia

Author

Maren Darsow

Atos MedicalORCID

Also Known As

M Darsow, M. Darsow, Maren Darsow, Michael Burkhardt, Vesna Bjelic-Radisic

40

Publications

779

Citations

8

H-Index

21

Concepts

All Affiliations

Atos MedicalKliniken Essen-MitteUniversity Hospital LeipzigLMU KlinikumDeutsches Archäologisches Institut, Zentrale
MD

About

Maren Darsow is an author at Atos Medical specializing in oncology, breast cancer, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

675

2

Public Health

1

1

12

3

Biostatistics

1

1

12

4

Obstetrics

1

1

12

5

Orthopaedics

1

1

232

Maren Darsow

×

6

Publications

719

Citations

6

H-Index

YearCitations

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber,

Annals of Oncology

2022

404

Long-Term Morbidity Following Axillary Dissection in Breast Cancer Patients – Clinical Assessment, Significance for Life Quality and the Impact of Demographic, Oncologic and Therapeutic Factors

Thorsten Kuehn, Wolfgang Klauss, Maren Darsow,

Breast Cancer Research and Treatment

2000

232

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

Ulrike Nitz, Oleg Gluz, Hans Kreipe,

Therapeutic Advances in Medical Oncology

2020

44

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Oleg Gluz, Sherko Küemmel, Ulrike Nitz,

Annals of Oncology

2023

16

Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial

Nadia Harbeck, Oleg Gluz, Sherko Küemmel,

Cancer Research

2021

12

Abstract GS4-03: Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+/HER2- trial

Sherko Küemmel, Oleg Gluz, Ulrike Nitz,

Cancer Research

2021

11

Page 1